GSK
GSKDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Execution on late‑stage pipeline readouts and positive FY2026 guidance drive re-rating to analyst high (near $53); successful commercial traction and favorable regulatory outcomes widen multiples.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.2.
What can break
Adverse clinical or regulatory outcomes for key pipeline assets
Momentum
23
Value
68
Sentiment
24
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $45.50 · Bull $53.00 · Bear $15.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-31 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $58.00
Why
Momentum23 · Δ7d -17.9
Value68 · Δ7d +0.2
Sentiment24 · Δ7d +1.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
23
26% active weight
Current posture
7d trendSoftening
Δ7d
-17.9
Δ21d
-6.6
Value
68
39% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.1
Sentiment
24
34% active weight
Current posture
7d trendImproving
Δ7d
+1.8
Δ21d
+0.9
Why this grade
Composite grade D. Momentum 22.8 / Value 67.8 / Sentiment 24.2
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$102.73B
Beta
0.68
Shares Out
2B
P/E (TTM)
13.6
P/S (TTM)
2.31
P/FCF (TTM)
34.24
Rev YoY
+8.6%
EPS YoY
+16.3%
Gross Margin
+72.8%
Op Margin
+23.4%
Net Debt
$19.25B
Current Ratio
0.79
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology